Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07985631 in Healthy Adult Participants
NCT07235150Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07985631 in IgA nephropathy (IgAN) (11 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) at 83 days, Number of Participants With Clinically Significant Abnormal Laboratory Parameters at 83 days and 2 more. Started Dec 2025; status: terminated.
02
Drugs
PF-07985631
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07235150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235150.